Highlights Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Market Closed - Nasdaq Other stock markets 04:00:05 2024-05-16 pm EDT			5-day change	1st Jan Change
10.42 ^USD	-2.39%		-22.49%	+28.23%

May. 13	Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained	MT
May. 13	Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says	May. 10	MT
Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates	May. 10	MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Iovance Biotherapeutics Q1 Loss Narrows -- Shares Higher After Hours	May. 09	MT
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Posts Q1 Revenue $715,000	May. 09	MT
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145	Mar. 04	DJ
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer	Mar. 04	CI
Iovance Biotherapeutics Q4 Loss Narrows, Posts Revenue	Feb. 29	MT
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Reports Q4 Revenue $482,000	Feb. 28	MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Iovance Shares Hits 52-Week High After Offering Pricing, FDA Approvals	Feb. 20	DJ
Dwindling Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	Feb. 20	MT
Iovance Biotherapeutics' Amtagvi for Advanced Melanoma Receives Accelerated FDA Approval	Feb. 16	MT
US FDA grants accelerated approval for Iovance's skin cancer cell therapy	Feb. 16	RE
Iovance Says Amtagvi Gets Accelerated Approval for Advanced Melanoma	Feb. 16	DJ
FDA approves Iovance Biotherapeutics cell therapy for skin cancer	Feb. 16	RE
Iovance Biotherapeutics, Inc.?s AMTAGVI? (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma	Feb. 16	CI
Iovance Biotherapeutics Pauses Lung Cancer Trial Following FDA's Clinical Hold	Dec. 27	MT
Iovance Biotherapeutics Says US FDA Halted Lung Cancer Trial After Participant's Death; Shares Fall Pre-Bell	Dec. 27	MT
Iovance Shares Fall Premarket As FDA Places Study On Hold After Patient Death	Dec. 27	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Highlights

Filters